Chronic Kidney Disease and Outcomes after TAVR in Patients with Severe Peripheral Arterial Disease: Insights from the Hostile Registry
Gianluca Anastasia, Tullio Palmerini, Francesco Saia, Antonio Giulio Bruno, Won-Keun Kim, Alessandro Iadanza, Ole De Backer, Francesco Burzotta, Nicolas M Van Mieghem, Thomas Pilgrim, Claudia Tiziana Aranzulla, Max M Meertens, Michael Joner, Francesco Meucci, Stefan Toggweiler, Luca Testa, Sergio Berti, Matteo Montorfano, Daniel Braun, Fausto Castriota, Marco De Carlo, Marco Barbanti, Francesco Tartaglia, Georg Nickenig, Tommaso Piva, Azeem Latib, Chiara Fraccaro, Ran Kornowski, Antonio L Bartorelli, Mohamed Abdel-Wahab, Matteo Vercellino, Italo PortoAbstract
Background
Chronic kidney disease (CKD) often coexists with aortic stenosis and worsens outcomes after transcatheter aortic valve replacement (TAVR). CKD is also associated with peripheral artery disease (PAD), but its impact in severe PAD patients undergoing TAVR remains unclear.
Aim
To evaluate the effect of CKD on PAD severity and outcomes after TAVR.
Methods
The HOSTILE registry included patients with severe PAD undergoing TAVR via transfemoral access (TFA, 30%) after iliofemoral revascularization, transalternative access (32%), or transthoracic access (38%). Patients were stratified by estimated glomerular filtration rate (eGFR) into low (≤48.0 mL/min; n=565) and intermediate/high (>48.0 mL/min; n=1,130) groups. The primary endpoint was major adverse events (MAEs) at 30 days and 12 months, adjusted using propensity score and overlap weighting.
Results
PAD characteristics were comparable across eGFR strata. Low eGFR was associated with higher 30-day MAEs (aHR 1.24, p=0.018), mainly driven by major vascular complications (aHR 1.32, p=0.006). At 1 year, MAEs (aHR 1.28, p=0.003) and mortality (aHR 1.53, p=0.002) remained increased, although landmark analysis suggested predominantly peri-procedural risk. Using an eGFR cut-off of 30 mL/min confirmed worse 30-day and 1-year MAEs, mortality, and cardiac death, with increased 1-year bleeding. In TFA patients, low eGFR predicted higher 30-day MAEs (aHR 1.77, p=0.002) and mortality (aHR 2.83, p=0.025), and 1-year MAEs (aHR 1.77, p=0.001) and mortality (aHR 2.31, p=0.003), with significant access–eGFR interaction.
Conclusions
In severe PAD patients undergoing TAVR, CKD amplifies peri-procedural risk, especially early vascular complications. Although TFA remains associated with better outcomes, its benefit appears attenuated in patients with renal dysfunction.